STAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midterms

Health industry leaders are still adjusting to the new rules of President Trump’s Washington and now face another potential shift. November’s midterm elections are likely to shake up key health policy debates, including Medicaid funding and the price of medication. That is especially true if Democrats seize control of a chamber of Congress, though any major policymaking would still require Trump’s signature.

The article draws on interviews with nearly a dozen health industry leaders and lobbyists to identify the most important questions about federal policy after the midterms. It is written by Daniel, who covers the intersection of the health industry and the federal government, including corporate influence in government, the health consequences of federal policies, and the politics of health care; confidential tips can be sent via Signal.

How those policy questions are answered will have wide-ranging impacts for America’s health system, science, and patients. The item is a STAT+ exclusive story, and the rest of the article is available only to subscribers.